149 results about "Phenylacetones" patented technology

The invention relates to an Escherichia coli engineering strain for producing 2, 3-pentanediol as well as a construction method and application of the Escherichia coli engineering strain, and the method comprises the following steps: constructing recombinant plasmids pACYC-IlvA *-ThrA * BC for expressing an IlvA * gene of threonine deaminase, a ThrA gene of asparaginic acid kinase I, a Thr B gene of homoserine kinase and a ThrC gene of threonine synthetase; the method comprises the following steps: constructing a recombinant plasmid pRSF-Ilv2C-Aro10 for expressing an Ilv2C gene of acetohydroxy acid synthetase and an Aro10 gene of propiophenone dehydrogenase; and chemically converting the recombinant plasmid pACYC-IlvA *-ThrA * BC and the recombinant plasmid pRSF-Ilv2C-Aro10, and transferring the recombinant plasmid pACYC-IlvA *-ThrA * BC and the recombinant plasmid pRSF-Ilv2C-Aro10 into escherichia coli so as to obtain the escherichia coli engineering strain for producing the 2, 3-pentanediol. According to the escherichia coli engineering strain, the biosynthesis of 1.61 g / L of 2, 3-pentanediol is realized by using L-threonine and 40 g / L of glucose.

The invention discloses a preparation method of a 32P-loaded ultrathin flaky chitosan hydrogel applicator. The preparation method comprises the following steps: (1) preparing a chitosan aqueous solution; (2) dropwise adding methacrylic anhydride into the chitosan aqueous solution for reaction to obtain methylacryloylated chitosan; (3) preparing a methylacryloyl chitosan aqueous solution; (4) adding 2-hydroxy-4 '-(2-hydroxyethoxy)-2-methyl propiophenone into the methylacryloylated chitosan aqueous solution to obtain a chitosan hydrogel precursor solution, and (5) coating the inner wall of a mold made of a polytetrafluoroethylene material with a super-hydrophilic coating; (6) adding the Na2H32PO4 aqueous solution and the chitosan hydrogel precursor solution into a mold, stirring, and carrying out illumination curing; and (7) taking out the cured hydrogel and packaging the hydrogel between two layers of transparent adhesive tapes. According to the application, the ultrathin hydrogel applicator can be prepared, so that the blocking of the hydrogel material to rays is reduced, and the curative effect of the applicator is enhanced.

The invention discloses a high-yield delta-tocotrienol genetically engineered bacterium and application thereof, and belongs to the technical field of gene recombination. The invention discloses a genetically engineered bacterium for high yield of delta-tocotrienols, which is characterized in that yarrowia lipolytica ATCC MYA-2613 is used as an original strain, and a ku70 gene is knocked out; the gene is used for expressing and coding 4-hydroxyphenylpyruvate dioxygenase, the gene is used for coding uromelanic acid phytate transferase and the gene is used for coding tocopherol cyclase; intensifying a shikimic acid pathway; a mevalonic acid pathway is strengthened; an isopentenol path is introduced; carrying out protein fusion on the HPD and the HPT; truncating a signal peptide of a gene encoding a tocopherol cyclase and back-filling a leucine defect. The genetically engineered bacterium constructed by the invention has industrial stability, can be amplified by more than 10 times in a 2L fermentation tank level compared with a shake flask level, can produce 616.45 mg / L of delta-tocotrienol after being cultured for 240 hours, and has industrial application prospects.

The invention provides p-hydroxymandelic acid synthetase, a gene, a mutant of the p-hydroxymandelic acid synthetase and application of the p-hydroxymandelic acid synthetase in asymmetric synthesis of (S)-mandelic acid. The p-hydroxymandelic acid synthetase disclosed by the invention is derived from actinomycetes Actinokineospora auranticola, the amino acid sequence of the p-hydroxymandelic acid synthetase is as shown in SEQ ID NO.1, and a mutant of the p-hydroxymandelic acid synthetase is obtained by performing single-point mutation or multi-point combined mutation on glutamic acid at the 187th site, isoleucine at the 189th site and threonine at the 211th site of the amino acid sequence as shown in SEQ ID NO.1. The p-hydroxymandelic acid synthetase and the mutant thereof can convert phenylpyruvic acid into (S)-mandelic acid with high optical purity, have the advantages of mild reaction conditions, simplicity and convenience in operation, safety, environment friendliness and the like, and have a very good industrial application prospect.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

The present invention provides an SLC6A19 inhibitor compound, a pharmaceutical composition, a preparation method, and a use. The compound has a good SLC6A19 inhibitory effect, and is used for the treatment of SLC6A19-mediated disorders and / or diseases, such as phenylketonuria, and the preparation of drugs for such disorders or diseases.

Disclosed herein are inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPD or HPPD) that have decreased inhibitory activity against sepiapterin reductase (SPR). Disclosed herein are methods of administering an HPD inhibitor alone or in combination with a diet low in tyrosine and / or phenylalanine, with or without dihydrobiopterin (BH2) and / or tetrahydrobiopterin (BH4) supplementation and / or monoamine salvage therapy. The compounds of the present disclosure can be used to treat conditions responsive to modulation or inhibition of HPD, such as inborn errors of metabolism, including tyrosinemia. The compounds of the present disclosure can also be used as herbicides to control weeds.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

The invention relates to a yarrowia lipolytica strain for producing tyrosol as well as a construction method and application of the yarrowia lipolytica strain, and belongs to the technical field of genetic engineering. According to the present invention, ScADH6, ScARO10F138L and D218G genes are expressed in the yarrowia lipolytica W29 [delta] KU70; the shikimic acid feedback inhibition is relieved by expressing the Y1ARO3K225L gene, the Y1ARO4K2214 gene and the Y1AR07G139S gene; pmLAAD, EcTyrAM53I and A354V genes are introduced, so that the conversion from FAD to FADH2 is promoted, and the supply of NADH (Nicotinamide Adenine Dinucleotide Hormone) in cytoplasm is enhanced; a 4-hydroxyphenylpyruvate dioxygenase (HPD) gene is knocked out; and overexpressing Y1DHS1, Y1DHS2 and Y1DHS3 genes of a shikimic acid pathway to obtain the yarrowia lipolytica strain HY5 for producing tyrosol. The invention lays a foundation for industrial production of tyrosol, and has important social significance and economic value.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

The present invention discloses a pyruvate decarboxylase mutant with improved catalytic efficiency and its application. The present invention constructs a pyruvate decarboxylase mutant derived from Candida tropicalis for catalytic production of 4-hydroxyphenylacetaldehyde. The catalytic half-life (5.7 h) and TTN (24,600) of the mutant of the present invention are increased by 2.85 times and 2.07 times respectively compared with the control, and the mutant exhibits high decarboxylation activity. When the obtained mutant of the present invention uses 4-hydroxyphenylpyruvic acid as a substrate and reacts for 12 h at 25 °C and pH 6.5, the yield of 4-hydroxyphenylacetaldehyde can reach 5.08 g / L, and the molar conversion rate of the substrate reaches 67.28%. By adopting the method of the present invention, the production capacity of the unit catalyst and the reaction efficiency of the catalyst are improved, and the industrialization process of producing 4-hydroxyphenylacetaldehyde by the enzyme conversion method is accelerated.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

This invention discloses a method for preparing a biomimetic actuating material based on inkjet printing patterned construction of a reed inner membrane hydrogel composite. The method includes inkjet printing a reed inner membrane; adding N-isopropylacrylamide, N,N-methylenebisacrylamide, and 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone to an aqueous solution of nano-clay to obtain a hydrogel prepolymer; placing the inkjet-printed reed inner membrane on a glass slide, adding the hydrogel prepolymer, covering and sealing it, and then placing it in ice water for photopolymerization to obtain the reed inner membrane hydrogel composite biomimetic actuating material. This invention uses an inkjet printer to print pigment ink onto the surface of a natural reed inner membrane for patterning, and then rapidly forms a strong mechanical interlocking structure with poly(N-isopropylacrylamide) hydrogel, resulting in strong bonding. The method is simple, and the actuating material exhibits excellent photothermal conversion efficiency, mechanical properties, and patterning capabilities, thereby enabling rapid actuation, ultra-high power actuation, and various complex biomimetic actuator designs.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

The invention discloses a recombinant microorganism for producing hydroxytyrosol as well as a construction method and application of the recombinant microorganism. According to the recombinant microorganism, 3-deoxy-D-arabinoheptulose-7-phosphate synthetase aroGfbr, chorismate mutase / pre-benzoic acid dehydrogenase tyrAfbr, 4-hydroxyphenylacetic acid 3-hydroxylase HpaBC, phenylpyruvate decarboxylase ARO10 and alcohol dehydrogenase ADH6 are subjected to overexpression, and the recombinant microorganism can be used for preparing the recombinant microorganism. The genome of the gene naturally comprises a citrate synthase coding gene gltA and a tyrosine aminotransferase coding gene tyrB; the original promoter of the gltA and / or the original promoter of the tyrB are / is replaced by a time sequence promoter PrrnC-37. When the recombinant microorganism is used for producing hydroxytyrosol, the production efficiency can be improved, and the production cost of hydroxytyrosol can be reduced.

Methods and devices are provided for capturing and using quantitative and qualitative results from point-of-collection devices for different diagnostic assays on a mobile device application. In one nonlimiting embodiment, these methods and devices are used in the diagnosis and / or monitoring of phenylketonuria (PKU).

The present disclosure relates to an optimized PAH gene and expression cassette and uses thereof, and discloses a polynucleotide molecule encoding a PAH protein. The polynucleotide molecule, expression cassette, expression vector, viral particle, and / or pharmaceutical composition disclosed herein can be used to effectively, sustainably, and stably express human PAH in the liver at a relatively low dose, thereby maintaining the phenylalanine concentration in a subject's blood at a low level for a long period of time and stably, and can be used to treat phenylketonuria.

The invention provides genetically engineered saccharomycetes capable of simultaneously producing baicalein and baicalin as well as a construction method and application of the genetically engineered saccharomycetes. According to the invention, by weakening or deleting a glucose 5-phosphate dehydrogenase gene (ZWF1) and phenylpyruvate decarboxylase genes ARO10 and PDC5 in a saccharomyces cerevisiae genome and enhancing the expression of a pre-benzoic acid dehydratase gene Pha2, the metabolic flow of a shikimic acid pathway is increased, the aldrin pathway is blocked, and the yield of the shikimic acid pathway is increased. Therefore, the yield of L-phenylalanine serving as a starting material for synthesizing baicalein and baicalin is increased; meanwhile, exogenous genes PAL, 4CL, CHS, CHI, FNSII, F6H, CPR and F7GAT are integrated onto the genome by virtue of a gene recombination technology, so that baicalein and baicalin are produced from the beginning by taking glucose and glycerol as a mixed carbon source without adding precursor substances such as exogenous L-phenylalanine or malonyl CoA and the like.

The invention relates to an expiratory gas marker for evaluating a mental fatigue state, and a method and a device for identifying the mental fatigue state. The expired gas marker at least comprises an organic compound combination consisting of oxalic acid, 3-phenyllactic acid, benzene, acetone and 3-methylpentane; oxalic acid, 3-phenyllactic acid, benzene, acetone and 3-methylpentane in exhaled air are associated with mental fatigue, and a brand-new biomarker combination with higher specificity is provided. In addition, a new modal metabolic data is provided for mental fatigue discrimination, and a multi-modal mental fatigue diagnosis model based on VOCs-HRV-PVT is constructed.

Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and / or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and / or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.

The invention discloses a method for preparing (S)-(-)-1-amphetamine. According to the method, propiophenone serves as a substrate and is converted into (S)-(-)-1-amphetamine under the catalytic action of imine reductase and ammonia water, the conversion rate is larger than or equal to 99%, and the ee value of the product is larger than or equal to 99%. The method disclosed by the invention is simple to operate and high in atom economy, and can be used for industrial production.

The invention discloses application of phenylpyruvic acid in prevention and control of citrus canker, and belongs to the field of treatment of agricultural canker. The invention discloses a new application of phenylpyruvic acid in treating and / or preventing citrus canker, and the effective dosage of phenylpyruvic acid is 0.01-1.5 M. The phenylpyruvic acid is externally applied, so that the scab area of the citrus canker can be reduced to a great extent, and the attack degree of the canker is reduced. In addition, the content of phenylpyruvic acid in citrus can be increased through multiple technologies, and the phenylpyruvic acid can be used for canker-resistant molecular breeding.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a composition for crowds suffering from phenylketonuria as well as a preparation method and application of the composition. The composition is prepared from the following raw materials in parts by weight: 20 to 50 parts of carbohydrate, 9 to 25 parts of fat, 25 to 52 parts of compound amino acid, 0.02 to 0.2 part of vitamin, 2 to 6 parts of mineral substances and 0.5 to 12 parts of other nutrient components, and the other nutrient components comprise choline, L-carnitine and gynura divaricata powder. The formula food for the special medical purpose is balanced in nutrition and good in palatability, has the effects of improving skin symptoms and resisting oxidation, and has a good application prospect.

Provided herein are phenylalanine-degrading enzyme variants for use in degrading phenylalanine and in treating phenylketonuria (PKU). More specifically, provided herein are phenylalanine-degrading enzyme variants that exhibit increased thermal stability and physicochemical resistance as measured by residual phenylalanine-degrading activity following challenge.

This invention discloses a load 32 The preparation method of the ultrathin sheet-like chitosan hydrogel applicator of P includes: (1) preparing a chitosan aqueous solution; (2) adding methacrylic anhydride to the chitosan aqueous solution to obtain methacrylated chitosan; (3) preparing a methacrylated chitosan aqueous solution; (4) adding 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylphenylacetone to the methacrylated chitosan aqueous solution to obtain a chitosan hydrogel precursor solution; (5) coating the inner wall of a polytetrafluoroethylene mold with a superhydrophilic coating; (6) adding Na2H 32 PO4 aqueous solution and chitosan hydrogel precursor solution are added to the mold, stirred and then cured by light; (7) the cured hydrogel is taken out and sealed between two layers of transparent tape. This application can prepare an ultra-thin hydrogel applicator, thereby reducing the obstruction of radiation by the hydrogel material itself and enhancing the therapeutic effect of the applicator.

Disclosed are naphthyl compounds comprising a ureido piperidine-1-carboxamide or ureido piperidine-1-formate moiety, compositions thereof, and methods of use thereof for treating or preventing diseases or conditions associated with abnormal levels of amino acids, such as phenylketonuria, hyperphenylalaninemia, diabetes, and chronic kidney disease, by modulating SLC6A19 transport.

Provided herein are phenylalanine-degrading enzyme variants for use in degrading phenylalanine and in treating phenylketonuria (PKU). More specifically, provided herein are phenylalanine-degrading enzyme variants that exhibit increased thermal stability and physicochemical resistance as measured by residual phenylalanine-degrading activity following challenge.

The invention provides a phenylpyruvate decarboxylase mutant with multi-site mutation and application of the phenylpyruvate decarboxylase mutant in production of tyrosol, and belongs to the technical field of bioengineering. The problem of low yield of tyrosol is solved. The phenylpyruvate decarboxylase mutant comprises a phenylpyruvate decarboxylase mutant, and the phenylpyruvate decarboxylase mutant is obtained by mutating any two or three sites of the 93rd site, the 106th site, the 153rd site, the 220th site, the 242nd site, the 273rd site and the 285th site by taking amino acid as shown in SEQ ID NO.2 as a starting sequence. The method is mainly used for increasing the yield of tyrosol.